(RTTNews) - Glucotrack, Inc. (GCTK), a medical technology ... This milestone study, which aimed to evaluate the safety of the implant, use, and removal of the CBGM sensor lead, confirms the ...

The study met its primary endpoint, with no procedure or device related serious adverse events reported from implant through seven days post-removal of the CBGM sensor lead. Glucotrack (NASDAQ ...

Glucotrack calls its device, which has no external on-body component, a continuous blood glucose monitor (CBGM). The implant is around the length and thickness of three US nickels, with a total ...

Leading diabetes researcher and clinician joins Glucotrack as Company advances development of long-term implantable blood glucose monitoring technologyRUTHERFORD, N.J., Feb. 26, 2025 (GLOBE ...

Glucotrack, Inc. GCTK reports it has achieved a significant milestone in its mission to transform diabetes management through three distinct advances: direct blood glucose measurement, hassle-free ...

RUTHERFORD, NJ – Glucotrack, Inc. (NASDAQ:GCTK), a medical device company with a market capitalization of $3.54 million, disclosed the completion of several transactions involving unregistered ...

Rutherford, NJ., Feb. 04, 2025 (GLOBE NEWSWIRE) -- Glucotrack, Inc. (Nasdaq: GCTK), a medical technology company focused on the design, development, and ...

DETROIT, MICHIGAN - February 25, 2025 (NEWMEDIAWIRE) - Glucotrack, Inc. (NASDAQ: GCTK) reports it has achieved a significant milestone in its mission to transform diabetes management through three ...

RUTHERFORD, NJ – Glucotrack, Inc. (NASDAQ:GCTK), a medical device company with a market capitalization of $3.54 million, disclosed the completion of several transactions involving unregistered sales ...

Glucotrack Commences Transition From Concept To Reality With Breakthrough Clinical Trial 25.02.2025 / 14:58 CET/CEST The issuer is solely responsible for the content of this announcement. By JE ...